GC Green Cross Wellbeing "Intae Pan Hydrolysate 'Lynek' Ligament Regeneration Effect"

[Asia Economy Reporter Cho Hyun-ui] GC Green Cross Wellbeing announced on the 17th that a paper confirming the ligament treatment effects of the human placental hydrolysate 'Lynek' was published in the SCI-level international journal 'Biological and Pharmaceutical Bulletin.'

The company explained that the paper confirmed another potential treatment for musculoskeletal diseases with Lynek, following its potential to prevent sarcopenia. Lynek is an injectable drug approved to improve liver function in patients with chronic liver disease and is made from human placental hydrolysate extracted from the human placenta.

The study was conducted through animal and cell experiments. In the animal experiment group with ligament injury, administration of Lynek resulted in reduced inflammation in the damaged ligament after four weeks. Additionally, the ligament injury evaluation index recovered to the level of normal ligaments.

When Lynek was applied to fibroblasts derived from the Achilles tendon, the expression of proteins related to ligament regeneration, such as collagen, increased by more than 40% compared to the control group. Professor Kim Beom-su of Inha University Orthopedics, who participated in the study, said, "Through this study, we confirmed that Lynek can help alleviate inflammation and regenerate damaged ligaments," adding, "As the number of chronic pain patients rapidly increases, Lynek could become a new alternative for pain treatment drugs."

This content was produced with the assistance of AI translation services.